KARD
Kardigan, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kardigan, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. Our management team includes leaders from MyoKardia, Inc. (“MyoKardia”) with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy. Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes. We were incorporated under the laws of the State of Delaware in August 2023 under the name EnCarda, Inc., and changed our name to Kardigan, Inc. in December 2024. Our principal executive offices are located in Princeton, NJ.
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. Our management team includes leaders from MyoKardia, Inc. (“MyoKardia”) with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy. Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes. We were incorporated under the laws of the State of Delaware in August 2023 under the name EnCarda, Inc., and changed our name to Kardigan, Inc. in December 2024. Our principal executive offices are located in Princeton, NJ.
No thesis.
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Kardigan, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Kardigan, Inc..
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| Schf (gpe) | $403.5M | 29.49% | new |
| FMR | $212.5M | 15.53% | new |
| Perceptive | $195.6M | 14.30% | new |
| T. Rowe Price | $100.3M | 7.33% | new |
| Capital Research Global Investors | $85.8M | 6.27% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Schf (gpe) | $403.5M | 29.49% | new |
| FMR | $212.5M | 15.53% | new |
| Perceptive | $195.6M | 14.30% | new |
| T. Rowe Price | $100.3M | 7.33% | new |
| Capital Research Global Investors | $85.8M | 6.27% | new |
Expected move
No implied move.
Kardigan, Inc.
14.70
−0.86 · −5.54%
—
—